These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37195421)

  • 1. Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
    Evans JV; Suman S; Goruganthu MUL; Tchekneva EE; Guan S; Arasada RR; Antonucci A; Piao L; Ilgisonis I; Bobko AA; Driesschaert B; Uzhachenko RV; Hoyd R; Samouilov A; Amann J; Wu R; Wei L; Pallerla A; Ryzhov SV; Feoktistov I; Park KP; Kikuchi T; Castro J; Ivanova AV; Kanagasabai T; Owen DH; Spakowicz DJ; Zweier JL; Carbone DP; Novitskiy SV; Khramtsov VV; Shanker A; Dikov MM
    J Natl Cancer Inst; 2023 Nov; 115(11):1404-1419. PubMed ID: 37195421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
    Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
    Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Release of adenosine-induced immunosuppression: Comprehensive characterization of dual A
    Dziedzic K; Węgrzyn P; Gałęzowski M; Bońkowska M; Grycuk K; Satała G; Wiatrowska K; Wiklik K; Brzózka K; Nowak M
    Int Immunopharmacol; 2021 Jul; 96():107645. PubMed ID: 33894488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8
    Chen S; Akdemir I; Fan J; Linden J; Zhang B; Cekic C
    Cancer Immunol Res; 2020 Aug; 8(8):1064-1074. PubMed ID: 32381524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
    Sorrentino C; Miele L; Porta A; Pinto A; Morello S
    Oncotarget; 2016 Sep; 7(39):64274-64288. PubMed ID: 27590504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model.
    Sorrentino C; Miele L; Porta A; Pinto A; Morello S
    Oncotarget; 2015 Sep; 6(29):27478-89. PubMed ID: 26317647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.
    Iannone R; Miele L; Maiolino P; Pinto A; Morello S
    Neoplasia; 2013 Dec; 15(12):1400-9. PubMed ID: 24403862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
    Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
    J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
    Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of JunB in adenosine A2B receptor-mediated vascular endothelial growth factor production.
    Ryzhov S; Biktasova A; Goldstein AE; Zhang Q; Biaggioni I; Dikov MM; Feoktistov I
    Mol Pharmacol; 2014 Jan; 85(1):62-73. PubMed ID: 24136993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy.
    Guan S; Suman S; Amann JM; Wu R; Carbone DP; Wang J; Dikov MM
    Neoplasia; 2022 Oct; 32():100824. PubMed ID: 35914370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of adenosine A2b receptor overexpression in tumor progression.
    Sepúlveda C; Palomo I; Fuentes E
    Life Sci; 2016 Dec; 166():92-99. PubMed ID: 27729268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.
    Chiappori AA; Creelan B; Tanvetyanon T; Gray JE; Haura EB; Thapa R; Barlow ML; Chen Z; Chen DT; Beg AA; Boyle TA; Castro J; Morgan L; Morris E; Aregay M; Hurtado FK; Manenti L; Antonia S
    Clin Cancer Res; 2022 Jun; 28(11):2313-2320. PubMed ID: 35254415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium Phosphate-Reinforced Metal-Organic Frameworks Regulate Adenosine-Mediated Immunosuppression.
    Liang L; Yang LL; Wang W; Ji C; Zhang L; Jia Y; Chen Y; Wang X; Tan J; Sun ZJ; Yuan Q; Tan W
    Adv Mater; 2021 Nov; 33(45):e2102271. PubMed ID: 34554618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A
    Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
    J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of adenosine A2B receptor in radiation-induced translocation of epidermal growth factor receptor and DNA damage response leading to radioresistance in human lung cancer cells.
    Kitabatake K; Yoshida E; Kaji T; Tsukimoto M
    Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129457. PubMed ID: 31678144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of A2B Receptor in DNA Damage Response and Radiosensitizing Effect of A2B Receptor Antagonists on Mouse B16 Melanoma.
    Tanaka Y; Kitabatake K; Abe R; Tsukimoto M
    Biol Pharm Bull; 2020 Mar; 43(3):516-525. PubMed ID: 31866630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine A2B receptor blockade slows growth of bladder and breast tumors.
    Cekic C; Sag D; Li Y; Theodorescu D; Strieter RM; Linden J
    J Immunol; 2012 Jan; 188(1):198-205. PubMed ID: 22116822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.